BeStock  
Stocks › Gene Editing › BEAM

Beam Therapeutics BEAM

US equityMarket cap rank #2634AI medical concept stocksGene Editing
$20.90 −$0.04 (-0.19%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $21.66 +3.65%
Open$20.60
Prev close$20.94
Day range$20.54 – $22.10
Volume3.89M
Market cap$2.16B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-25.9x
CheapRich

Near the bottom of its 5-year range · 15th percentile, 5-year average -15.1x

Price / book2.5x
CheapRich

Below its usual level · 34th percentile, 5-year average 3.1x

#3456 of 5330 stocks by PB (1 = cheapest)

Price / sales16.1x
CheapRich

Below its usual level · 21st percentile, 5-year average 384.8x

#4674 of 5155 stocks by PS (1 = cheapest)

P/E over five years

-83x-54x-25x5xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$27.70
Price vs. fair value-24.5%Trading below the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyHigh
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 2.48 – 3.10 34% (cheaper than usual) #3456 of 5330 (1 = cheapest)
PE -25.94 -4.37 -15.08 15% (cheaper than usual) –
PS 16.11 121.14 384.79 21% (cheaper than usual) #4674 of 5155 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on BEAM.

Sign in to join the discussion.

Scroll to Top